STEEPLE bleeding criteria: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Steeple Bleeding Criteria== | ==Steeple Bleeding Criteria (DO NOT EDIT)<ref name="pmid19171853">{{cite journal| author=Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J et al.|title=Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. | journal=Circulation | year= 2009 | volume= 119 | issue= 5 | pages= 680-6 | pmid=19171853 |doi=10.1161/CIRCULATIONAHA.108.803528 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19171853 }} </ref>== | ||
{{cquote| | {{cquote| | ||
Safety and Efficacy Of [[Enoxaparin]] In [[Percutaneous Coronary Intervention]] Patients: An International Randomized Evaluation | Safety and Efficacy Of [[Enoxaparin]] In [[Percutaneous Coronary Intervention]] Patients: An International Randomized Evaluation | ||
'''Major Bleeding''' | '''Major Bleeding''' | ||
* Fatal [[bleeding]] | * Fatal [[bleeding]] |
Revision as of 17:46, 27 March 2013
Bleeding Microchapters |
Treatment |
---|
Reversal of Anticoagulation and Antiplatelet in Active Bleed |
Perioperative Bleeding |
STEEPLE bleeding criteria On the Web |
American Roentgen Ray Society Images of STEEPLE bleeding criteria |
Risk calculators and risk factors for STEEPLE bleeding criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Steeple Bleeding Criteria (DO NOT EDIT)[1]
“ |
Safety and Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation Major Bleeding
Minor
|
” |
References
- ↑ Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J; et al. (2009). "Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial". Circulation. 119 (5): 680–6. doi:10.1161/CIRCULATIONAHA.108.803528. PMID 19171853.